Data on AbC-19 as CDx for Pfizer-BioNTech Vaccine

24 February 2021 - 07:00
RNS Number : 1093Q
Abingdon Health PLC
24 February 2021

Abingdon Health Notes Announcement by UK-RTC

on Performance of AbC-19TM Rapid IgG-Spike Antibody Tests as a companion test to the Pfizer-BioNTech COVID-19 vaccine


Study indicates that vaccination programmes could benefit from determining an individual's antibody status both prior to and after vaccination


York, U.K. 24 February 2021: Abingdon Health plc ("the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, welcomes the announcement today by the members of the UK-RTC that presents new data examining the performance of the AbC-19TM rapid antibody test when used with 193 individuals that had received a single dose of the Pfizer-BioNTech COVID-19 vaccination. This initial study was performed at the University of Birmingham.


The sample population included a sub-set of 65 patients that had previously been infected with COVID-19, and 128 that had no previous infection. The highlights of the data/study are as follows:


·    The AbC-19TM rapid antibody test was effective in demonstrating the immune response of patients to the first dose of the Pfizer-BioNTech COVID-19 vaccine;


·    The study highlighted a differential immune response of two cohorts of patients: those previously infected with COVID-19 and those not infected; and


·    Patients previously infected with COVID-19 showed a stronger immune response to the first dose of the Pfizer-BioNTech COVID-19 vaccine;


The initial data from the study being performed at the University of Birmingham supports the rationale that vaccination programmes could benefit from determining an individual's antibody status not only after vaccination but also prior to vaccination Should these results continue to be seen in further studies, and with other vaccines, this demonstrates that the AbC-19 TM antibody test could potentially assist in patient stratification and resource management in overburdened international healthcare settings.


The AbC-19™ Rapid Test was used to test samples from individuals who had been given a single dose of the Pfizer-BioNTech COVID-19 vaccine. In total 193 individuals who had received a COVID-19 vaccine were tested for the presence of IgG antibodies to the full trimeric spike using the AbC-19TM test.


Of the patients involved in the study, the AbC-19TM rapid test identified 181 (94%) as testing positive for the presence of IgG antibodies to COVID-19, with some samples from those with previous infection demonstrating a positive result as little as 1-4 days post vaccination. Using a cut-off of 13 days post-vaccination (which is the minimum recommendation for determining antibody status using the AbC-19TM rapid test) 137 out of 140 of samples, or 98% of patients, were identified as testing positive for the presence of IgG antibodies.


Using the WHO classification of the lateral flow device test line, results were classified as:


·    0 (negative)

·    1 (very weak but definitely reactive)

·    2 (medium to strong reactivity)

Of the 193 individuals examined, 128 (66%) patients were determined as not having a previous COVID-19 infection and thus naïve samples, with 65 (34%) patients identified as having a previous COVID-19 infection. 


When applying the above scoring to the samples taken 13 days after the single vaccination, 43.3% of the naïve samples scored medium to strong test line response with 53.8% showing a weaker response and 2.9% having a negative result. In contrast, those who had previously been infected with COVID-19 had a stronger response in 75% individuals, while 25% showed a weaker response with no negative results. It would be expected for the IgG anti-spike antibody levels to continue to rise with time and following a second vaccination.


Further studies are being performed to expand this data set and are expected to be available in the next few weeks.


About the UK-RTC


The UK Rapid Test Consortium (UK-RTC) was founded in response to a UK Government call for businesses to work together on a rapid antibody test to be rolled out nationally. Led by Abingdon Health, its members also include, BBI Solutions, CIGA Healthcare and Omega Diagnostics. The Abc-19TM is approved in Europe and the UK for professional use and is available for sale.


About the AbC-19™ Rapid Test 


The AbC-19™ Rapid Test is a single use test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus in human capillary whole blood. 


About Abingdon Health plc

Abingdon Health plc is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.


The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world.

Founded in 2008, Abingdon Health is headquartered in York, England.



Abingdon Health plc


Chris Yates

Chief Executive Officer

Via Consilium


Dr Chris Hand

Non-Executive Chairman


Melanie Ross

Chief Financial Officer



N+1 Singer

Sole Broker and NOMAD

Tel: +44 (0) 20 7496 3000


Shaun Dobson, Pete Steel and Alex Bond (Corporate Finance)


Tom Salvesen (Corporate Broking)




Financial PR

Tel: +44 (0) 7720 088 468


Matthew Neal

                         [email protected]

Mary-Jane Elliott             

Lindsey Neville



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Provided by: RNS
London AIM (United Kingdom)
Abingdon Health plc
Abingdon Health is a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries. Services offered by the Company to its clients including product development, regulatory support, technology transfer and commercial manufacturing....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More